Clinical Trial Update: A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating first-line capecitabine (Xeloda) plus bevacizumab in metastatic colorectal cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-01-22